Antiatherogenic small, dense HDL--guardian angel of the arterial wall? (Q34498148)

2 August 2017

1 reference

title

Antiatherogenic small, dense HDL--guardian angel of the arterial wall? (English)

1 reference

2 August 2017

Anatol Kontush

1

1 reference

PubMed ID

16505860

2 August 2017

M John Chapman

series ordinal

2

1 reference

2 August 2017

1 March 2006

1 reference

Nature Clinical Practice Cardiovascular Medicine

2 August 2017

1 reference

2 August 2017

3

1 reference

2 August 2017

144-153

1 reference

2 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpcardio0500

2 August 2017

0 references

cites work

Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

1 reference

7 January 2021

C-reactive protein comes of age.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Inflammation, atherosclerosis, and coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Mechanisms for oxidizing low-density lipoprotein. Insights from patterns of oxidation products in the artery wall and from mouse models of atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

High-density lipoprotein subfractions and risk of coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Atheroprotective effects of high-density lipoproteins

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Different effects of subclasses of HDL containing apoA-I but not apoA-II (LpA-I) on cholesterol esterification in plasma and net cholesterol efflux from foam cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Role of free apolipoprotein A-I in cholesterol efflux. Formation of pre-alpha-migrating high-density lipoprotein particles

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Dyslipidemia and inflammation: an evolutionary conserved mechanism.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Serum amyloid A (SAA): an acute phase protein and apolipoprotein

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Serum amyloid A and lipoprotein retention in murine models of atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Glycation impairs high-density lipoprotein function

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

HDL metabolism in hypertriglyceridemic states: an overview

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Effects of the neutral lipid content of high density lipoprotein on apolipoprotein A-I structure and particle stability

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI).

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Role of Serum Amyloid A During Metabolism of Acute-Phase HDL by Macrophages

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

The conformation of apolipoprotein A-I in high-density lipoproteins is influenced by core lipid composition and particle size: a surface plasmon resonance study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Inflammatory exposure and historical changes in human life-spans

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Niacin therapy in atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Effects of extended-release niacin on lipoprotein subclass distribution

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Apolipoprotein A-I(Milano): current perspectives

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Therapeutic approaches to raising plasma HDL-cholesterol levels

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Apolipoprotein A-I mimetic peptides

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0500

7 January 2021

Identifiers

DOI

10.1038/NCPCARDIO0500

1 reference

PubMed ID

16505860

Dimensions Publication ID

2 August 2017

0 references

1 reference

PubMed ID

16505860